NASDAQ Soins de santé Biotechnologie KOD

Kodiak Sciences Inc.

$ 36.14 1.20 %

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

CEO: Victor Perlroth - https://kodiak.com

Summary 30-Y Financials Dividend Analyst Historique indicateurs Possession / Senat
Price objectif

$63.75 76.40 %

Recommandation

Buy

DCF

$ 0.74

Loading data...

KOD vs S&P500

Loading data...

No data available.

Quick ratio

3.54

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-8.65

may indicate that the company is undervalued or has poor growth prospects.

EPS

-4.18

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-253.85 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-87.69 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

13.85

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

1.39

means it relies more on debt, which can increase financial risk.

Free cash flow per share

-2.39

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
1 indicates worrying financial health
Altman score
-3.43 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
3.42 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.51 indicates a moderate level of debt, which is generally acceptable but may present some risk
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.